- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00132314
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
CSP #555 - Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The purpose of the study is to assess the effectiveness of long-acting injectable risperidone on psychiatric inpatient hospitalization, schizophrenia symptoms, quality of life, medication adherence, side effects, and health care costs.
Objectives:
Primary: To evaluate the impact of long-acting intramuscular (IM) risperidone on risk of inpatient psychiatric hospitalization in comparison to standard oral antipsychotic treatment in a randomized controlled trial to be conducted with 450 veterans diagnosed with schizophrenia or schizoaffective disorder at 16 VA medical centers over three years.
Secondary: To evaluate adherence, health benefits, and costs of long-acting IM risperidone as compared to standard oral antipsychotic treatment as measured by: a) symptom reduction over 12 months, b) time to all-cause medication discontinuation, c) quality of life, d) VA and non-VA health service use and related costs, e) medication side effects, f) violent behavior, g) use of concomitant medication, and h) the incremental cost-effectiveness ratio.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Tuscaloosa, Alabama, Estados Unidos, 35404
- VA Medical Center, Tuscaloosa
-
-
California
-
Long Beach, California, Estados Unidos, 90822
- VA Medical Center, Long Beach
-
Palo Alto, California, Estados Unidos, 94304-1290
- VA Palo Alto Health Care System
-
-
Connecticut
-
West Haven, Connecticut, Estados Unidos, 06516
- VA Connecticut Health Care System (West Haven)
-
-
Florida
-
Miami, Florida, Estados Unidos, 33125
- VA Medical Center, Miami
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30904
- VA Medical Center, Augusta
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Jesse Brown VAMC (WestSide Division)
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02130
- VA Medical Center, Jamaica Plain Campus
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- John D. Dingell VA Medical Center, Detroit
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55417
- VA Medical Center, Minneapolis
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64128
- VA Medical Center, Kansas City MO
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68105-1873
- VA Medical Center, Omaha
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87108-5153
- New Mexico VA Health Care System, Albuquerque
-
-
New York
-
New York, New York, Estados Unidos, 10010
- New York Harbor HCS
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- VA Medical Center, Cleveland
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- VA Medical Center, Philadelphia
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Michael E. DeBakey VA Medical Center (152)
-
Waco, Texas, Estados Unidos, 76711
- Central Texas Veterans Health Care System - Waco
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98108
- VA Puget Sound Health Care System, Seattle
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age 18 years or older.
- Diagnosed with schizophrenia or schizoaffective disorder by the Structured Clinical Interview for Diagnosis (SCID) (Spitzer and First et al., 1996).
Patients should
- have been hospitalized in the two years before study entry on a psychiatric inpatient unit, or
- document explicit current evidence of increased use of outpatient services such as additional visits, day treatment or non-hospital residential treatment, increased dosage of medications or addition of concomitant psychotropic medications.
The b criterion will promptly be adjudicated by the study chairmen on a case-by case basis to insure credibility.
- .Adequate transportation is available and the participant lives within a travel time of less than 1.5 hours, allowing attendance at all scheduled visits.
- Use of an acceptable method of birth control by female patients who have a possibility of becoming pregnant (safety concerns).
- Able to demonstrate decisional capacity in order to give informed consent as assessed by the MacArthur Competence Assessment Tool (MacCAT) (Appelbaum and Grisso, 1996). Guardian consent is acceptable where applicable.
- Dually diagnosed patients with both schizophrenia and addictive disorders would be included in this study but should not be in need of acute detoxification for physiologic substance dependence (excluding nicotine) in the past 30 days.
Exclusion Criteria:
- Physiologic substance dependence requiring detoxification (excluding nicotine) in the past 30 days (substance abuse is not an exclusion).
- Intolerance of risperidone.
- Intolerance of intramuscular injection.
- Current treatment with depot antipsychotic medication.
- Current treatment with oral clozapine or presence of refractory schizophrenia that, in the treating psychiatrist's opinion, requires clozapine.
- Hepatic or renal problems AST or ALT (>2 times upper limit of normal);
- Elevated bilirubin (>1.2), BUN (>24), creatinine (>1.7).
- Unstable, serious medical condition or one requiring acute medical treatment, or anticipation of hospitalization for extended care.
- Dementia, epilepsy, insulin-dependent diabetes, anticoagulation with coumadin.
- Unstable living arrangements or not planning to remain in the area for the next year.
- Legal entanglements or pending legal charges with potential of incarceration.
- Assault or suicide gesture currently needing acute intervention.
- Concurrent participation in another clinical trial with an investigational drug during the last 30 days.
- Pregnant or lactating women or women planning to become pregnant.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Arm 1
long-acting injectable risperidone
|
long-acting injectable risperidone
|
Comparador Ativo: Arm 2
oral antipsychotic medication
|
doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Hospitalization-free Survival - Time to Event
Prazo: From randomization until date of first re-hospitalization, assessed up to 24 months
|
A hospitalization-free survival was defined as the time from the date of randomization to the time of a psychiatric hospitalization (in both VA and non-VA hospitals) or, in the case of patients who were hospitalized at randomization, the time from the date of discharge from the initial stay to subsequent hospitalization.
Patients without an event were censored at 24 months after the date of randomization.
|
From randomization until date of first re-hospitalization, assessed up to 24 months
|
Hazard Ratio for Hospitalization
Prazo: 24 months
|
Hazard ratio of LAI versus Oral for psychiatric hospitalization (in both VA and non-VA hospitals), after randomization up to 24 months, obtained from a Cox proportional hazards model.
|
24 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Robert A. Rosenheck, AB MD, VA Connecticut Health Care System (West Haven)
Publicações e links úteis
Publicações Gerais
- Rosenheck RA, Krystal JH, Lew R, Barnett PG, Thwin SS, Fiore L, Valley D, Huang GD, Neal C, Vertrees JE, Liang MH; CSP 555 Research Group. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia. Clin Trials. 2011 Apr;8(2):196-204. doi: 10.1177/1740774510392931. Epub 2011 Jan 26.
- Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011 Mar 3;364(9):842-51. doi: 10.1056/NEJMoa1005987. Erratum In: N Engl J Med. 2011 Mar 31;364(13):1281.
- Barnett PG, Scott JY, Rosenheck RA; CSP 555 Study Group. How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res. 2011 Aug;130(1-3):34-9. doi: 10.1016/j.schres.2011.03.033. Epub 2011 Apr 22.
- Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2012 May;73(5):696-702. doi: 10.4088/JCP.11m07070.
- Thwin SS, Hermes E, Lew R, Barnett P, Liang M, Valley D, Rosenheck R. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures. Psychiatry Res. 2013 Oct 30;209(3):291-6. doi: 10.1016/j.psychres.2013.01.016. Epub 2013 Mar 7.
- Hoblyn JC, Rosenheck RA, Leatherman S, Weil L, Lew R; CSP 555 Investigator Group. Veteran subjects willingness to participate in schizophrenia clinical trials. Psychiatr Q. 2013 Jun;84(2):209-18. doi: 10.1007/s11126-012-9240-4.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Transtornos Mentais, Desordem Mental
- Espectro da Esquizofrenia e Outros Transtornos Psicóticos
- Esquizofrenia
- Transtornos Psicóticos
- Efeitos Fisiológicos das Drogas
- Agentes Neurotransmissores
- Mecanismos Moleculares de Ação Farmacológica
- Depressores do Sistema Nervoso Central
- Agentes Tranquilizantes
- Drogas Psicotrópicas
- Agentes de Serotonina
- Agentes de Dopamina
- Antagonistas da Serotonina
- Antagonistas da Dopamina
- Risperidona
- Antipsicóticos
Outros números de identificação do estudo
- 555
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em IM risperidone
-
University of Illinois at ChicagoConcluídoLeucemia mielóide aguda | Leucemia mielóide crônica | Leucemia Aguda | Leucemia Linfoblástica | Linfoma não-HodgkinEstados Unidos
-
Fundación Eduardo AnituaRecrutamentoFormação de biofilmeEspanha
-
Asante Health SystemHealth Resources and Services Administration (HRSA)ConcluídoDoença Pulmonar Obstrutiva Crônica (DPOC) | Insuficiência Cardíaca Congestiva (ICC)Estados Unidos
-
AstraZenecaConcluídoVoluntário Saudável | Doença de Coronavírus 2019 (COVID-19)China
-
CurvaFix, Inc.RecrutamentoFratura Pélvica | Fratura Acetabular | Fratura do Anel Pélvico | Fratura Pélvica AcetábuloEstados Unidos
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH); Department of Health and Human ServicesRecrutamento
-
University Hospitals, LeicesterPublic Health England; Crucell Holland BV; National Institute of Biological Standards...Concluído
-
US Department of Veterans AffairsRetirado
-
Children's Fractures Interest Group, DenmarkRecrutamentoCriança, Somente | Complicação do Implante | Fratura do Antebraço | Cicatrização de Fraturas | Fixação de Fratura IntramedularDinamarca
-
Stryker Japan K.K.Desconhecido